Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.

Completed

Conditions studied: Intrahepatic Cholangiocarcinoma (Icc)

In brief

Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking. The EXOMIC study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to detect occult metastasis preoperatively in patients with resectable ICC.

Key facts

Study ID

NCT07224737

Run by

City of Hope Medical Center

People needed

230

Starts

2024-06-21

Expected to finish

2026-02-18

Last updated by the study team

2026-03-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed ICC (clinical stage I-III).
• Undergoing curative-intent hepatectomy.
• Availability of preoperative pasma or serum sample (≥200 µL).
• Standard staging imaging completed per institutional protocol.
• Written informed consent.

You may not qualify if…

• Extrahepatic cholangiocarcinoma or gallbladder cancer.
• Synchronous non-ICC malignancy.
• Inadequate clinical follow-up.
• Inability to consent.

Where it is running

• City of Hope Medical Center — Duarte, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.